Viamet Pharma Raises $18 Million
Viamet Pharmaceuticals Inc., a Morrisville, N.C.-based biotech company targeting metalloenzymes, has raised $18 million in Series B funding. Novartis Option Fund and Lilly Ventures co-led the round, and were joined by return backers Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.
7 July 2009•3 mins read
